Ranibizumab (Lucentis) Intravitreal Injection
Ranibizumab (Lucentis) is a humanized monoclonal antibody fragment that inhibits VEGF, used for treating wet age-related macular degeneration (AMD). It is presented as an intravitreal injection in measured doses for retail sale, qualifying under tariff item 3002.15.00 as an immunological product. This product regulates angiogenesis through immunological mechanisms.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| 🇨🇳China | Free | — | Free |
| 🇲🇽Mexico | Free | — | Free |
| 🇺🇸United States | Free | — | Free |
| 🇩🇪Germany | Free | — | Free |
| 🇯🇵Japan | Free | — | Free |
PGA flags (8)Show detailsHide detailsCFIAAll ProgramsRequiredECCCWildlife Enforcement - commodity may be regulated by ECCCRequiredHCBlood and Blood ComponentsMay be requiredHCCell, Tissues and OrgansMay be requiredHCHuman DrugsMay be requiredHCMedical DevicesMay be requiredHCNatural Health ProductsMay be requiredHCVeterinary DrugsMay be required
- CFIA
All Programs · Required
CANADIAN FOOD INSPECTION AGENCY: CFIA All Programs requires review / declaration data. CBSA's Single Window matching criteria match this classification number (Within Range 3002120021–3002150000).
- ECCC
Wildlife Enforcement - commodity may be regulated by ECCC · Required
ENVIRONMENT AND CLIMATE CHANGE CANADA: ECCC Wildlife Enforcement - commodity may be regulated by ECCC requires review / declaration data. CBSA's Single Window matching criteria match this classification number (Starts With 3002).
- HC
Blood and Blood Components · May be required
May require HC Blood and Blood Components depending on intended use (HC01) and Canadian product category (HC02). Matching criteria: Starts With 3002. Logic: MATCH IF (Valid HS Code) AND (Intended Use Code) AND (Valid Canadian Product Category).
- HC
Cell, Tissues and Organs · May be required
May require HC Cell, Tissues and Organs depending on intended use (HC01) and Canadian product category (HC26, HC27, HC28). Matching criteria: Starts With 3002. Logic: MATCH IF (Valid HS Code) AND (Intended Use Code) AND (Valid Canadian Product Category).
- HC
Human Drugs · May be required
May require HC Human Drugs depending on intended use (HC01, HC29, HC31) and Canadian product category (HC05, HC06); or intended use (HC02, HC07, HC31) and Canadian product category (HC05). Matching criteria: Starts With 3002; Starts With 3002. Logic: MATCH IF (Valid HS Code) AND (Intended Use Code) AND (Valid Canadian Product Category).
- HC
Medical Devices · May be required
May require HC Medical Devices depending on intended use (HC01, HC02, HC03, HC04, HC07, HC29, HC30) and Canadian product category (HC11, HC12, HC13, HC14). Matching criteria: Starts With 3002; Equal To 3002150000. Logic: MATCH IF (Valid HS Code) AND (Intended Use Code) AND (Valid Canadian Product Category).
- HC
Natural Health Products · May be required
May require HC Natural Health Products depending on intended use (HC01, HC02, HC05, HC07, HC29) and Canadian product category (HC15). Matching criteria: Starts With 3002. Logic: MATCH IF (Valid HS Code) AND (Intended Use Code) AND (Valid Canadian Product Category).
- HC
Veterinary Drugs · May be required
May require HC Veterinary Drugs depending on intended use (HC10) and Canadian product category (HC16, HC17); or intended use (HC07, HC11, HC12, HC14, HC29) and Canadian product category (HC16). Matching criteria: Starts With 3002; Starts With 3002. Logic: MATCH IF (Valid HS Code) AND (Intended Use Code) AND (Valid Canadian Product Category).
CBSA Single Window matching criteria, unknown
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If imported in bulk without retail packing
Bulk immunological products not in measured doses fall under this subheading.
If classified as a medicament
Therapeutic medicaments may be classified under heading 30.04.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Ensure the injection is in retail packaging with measured doses
• Provide batch records and certificates of analysis for customs
• Verify if a Health Canada authorization is needed before import
Related Products under Tariff item 3002.15.00
Adalimumab (Humira) Prefilled Syringe
Adalimumab (Humira) is a fully human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), used to treat autoimmune conditions such as rheumatoid arthritis and Crohn's disease. It is presented in pre-filled syringes with measured doses for retail sale, qualifying as an immunological product under tariff item 3002.15.00. This item covers immunological products put up in measured doses or in forms or packings for retail sale.
Adalimumab Prefilled Syringe for Psoriasis Treatment
Adalimumab, sold under the brand Humira, is a TNF inhibitor monoclonal antibody presented in 40 mg prefilled syringes for retail sale. It is used prophylactically to manage autoimmune psoriasis flares. As an immunological product put up in measured doses for retail sale, it is classified under tariff item 3002.15.00.
AstraZeneca Vaxzevria COVID-19 Vaccine
Vaxzevria is a COVID-19 vaccine using a chimpanzee adenovirus vector to express the SARS-CoV-2 spike protein, triggering an immune response. It is supplied in multi-dose vials for retail distribution, qualifying as an immunological product under tariff item 3002.15.00.
Atezolizumab (Tecentriq) Concentrate
Atezolizumab (Tecentriq) is a humanized monoclonal antibody targeting PD-L1, used in immunotherapy for bladder cancer and other malignancies. It is supplied as a concentrate for infusion in measured-dose vials for retail sale, meeting the criteria for tariff item 3002.15.00. This product directly regulates immunological processes through checkpoint inhibition.
Bavarian Nordic Imvamune Smallpox Vaccine
Imvamune is a non-replicating modified vaccinia Ankara vaccine for smallpox and mpox protection. It is an immunological product presented in measured doses for retail sale, fitting tariff item 3002.15.00.
Bevacizumab (Avastin) IV Solution
Bevacizumab (Avastin) is a humanized monoclonal antibody that blocks vascular endothelial growth factor (VEGF), used in treating colorectal and lung cancers. It is presented as an IV solution in measured-dose vials for retail sale, qualifying under tariff item 3002.15.00 as an immunological product. The product regulates immunological processes via angiogenesis inhibition.